Neurosense Therapeutics is trading 7.9% up at $7.50 in pre-market on September 28; no separate company-specific catalyst was identified. - The September 25 close was $6.95. - A September 25 update reported lower first-half losses and progress toward a targeted December 2026 Canadian filing for ALS treatment PrimeC; it did not link the update to share-price moves. - Major U.S. indices were lower amid risk-off sentiment, which does not explain the opposite move; no pre-market volume or activity details were provided.